Monthly Archives: September 2017

The Trabuco-An Early Weapon Of Mass Destruction

A Trabucos was an ancient medieval weapon used to demolition a structure or fire heavy rounds of boulders or other projectiles over the structure. It derived from the basic sling which used rocks to attack people and soon found itself larger and able to sling massive projectiles at stone structures such as walls and castles in order to bring them down and gain access to the opponents inside. The machine itself used a swinging arm in which the projectile was placed and gravity was used to catapult the projectile into the wall or structure.

The Trabucos was invented in China in the fourth century by Qiang Shen commander of the army in the Jurchen Jin dynasty, and became the weapon of choice for the Jin, Sui and Ming empires. Using the sling and lever concept it quickly found it’s way into the depository of some of the world’s most powerful armies and quickly spread throughout Europe, the Middle East, and Asia according to bandab.com.br.

According to spanishdict.com, there were different types of the machine ranging from the balancing Trabuco, the Blunderbuss which was used in Christian and Muslim countries, to the Warwolf that was used in the siege of Stirling Castle in Scotland which rendered their defenses such as moats and bridges indefensible. Statistics show that the armies that used the Trabuco were able to hold their ground and not retreat from the enemy so easily.

Another use for the weapon was an early form of biological warfare, in which they would fling infected bodies into the opposing area, so that the victims would contract the contagious disease and it would ultimately wipe them out, weakening their opponents defenses on youtube.com.

It is no wonder that the Trabucos and it’s various uses, would be known throughout history as one of the best weapons of choice. It later phased out to the modern cannon which used gun powder instead of gravity as the projection accelerator. Rocks and Boulders were replaced by cannons and missiles.

Search more about Trabuco: https://br.investing.com/news/mercado-de-a%C3%A7%C3%B5es-e-financeiro/bradesco-retomada-de-credito-a-partir-do-fim-de-2017-diz-trabuco-508466

Paul Mampilly: Research-Backed Investment Advice

Paul Mampilly is an American entrepreneur, research and investment analyst, and a former Wall Street bigwig. Paul is the man behind Profits Unlimited, a newsletter that dispenses investment advice to Americans. Over the years, Paul through the newsletter has gained popularity with many aspiring investors. He is often featured on television programs aired on Bloomberg TV, and CNBC among others.

As an investor, Paul has made some investments that yielded impressive returns. For example, his 2012 investment in Sarepta Therapeutics—a therapeutic drug development company—generated over 2000% profits in under 12 months. When he invested in Netflix in 2008, the company’s stock prices rose substantially enabling Paul to a make profit. Paul is an avid investor who believes that timing is the key to successful investments. Paul advises his audience to know when to make an investment in a company and when to divest from it. As at present, Paul has investment advice for his audience. And as usual, Paul’s information is backed by research.

Follow Paul Mampilly on LinkedIn

Paul has observed and realized an investment opportunity in electric car manufacturers. He believes that traditional vehicle manufacturers, using internal combustion engines, have uncertain future as the world is edging towards electric vehicles. Paul advises his audience to take the opportunity and invest in companies keen on developing electric cars. Such companies will soon be gold mines.

With the advent of technology, healthcare has been evolving rapidly. Paul believes that technology is yet to deliver the best in healthcare in the form of precision medicine. Precision medicine aims to personalize healthcare to suit individual needs. The guiding principle: no two persons are similar, and therefore each should be handled differently. Precision medicine is an evolving field, and Paul believes wise investors should take note of it.

Statistics estimate that millennials constitute the largest population segment in America. According to Paul on stockgumshoe.com, millennials have specific eating habits that require food or cooking ingredients to be delivered at their doorsteps.

He believes it is the best time for investors to put their money in food delivery systems tailored to meet the needs of millennials.

Paul has worked in many companies since 1991. He left Wall Street to focus on his family and use his experience to mentor investors.

Learn more about Paul Mampilly: http://releasefact.com/2017/09/how-paul-mampilly-created-the-fastest-growing-investment-newsletter/

[Top]

Eric Lefkofsky and the Tempus Solution to Cancer Care

Cancer is one of the most terrifying diagnosis that can be handed down to a patient sitting within their doctors office. Medical research is an industry unto itself and bright minds around the world are focused on finding a way to make that diagnosis just a little less intimidating. Eric Lefkofsky is one of the brighter tech minds coming out of Chicago in recent decades. He’s established himself as someone who can innovate within the specialty niche of data focused precision medicine. This specialty brought Lefkofsky to found his latest company, Tempus.

The healthcare industry is an industry that is always seemingly on the cutting edge of something new — and it’s important that it is. In order for lives to be saved, technological innovations have to be coming through the door at a record pace. A few years back the introduction of Electronic Health Records, otherwise known as EHRs, gave life to the industry. Now, years later, we know that they aren’t enough. Medical records are still notoriously sloppy and hard to corroborate between clinics and nowhere is this more apparent than within the realm of cancer-care. This is the niche that Tempus is diving into and this is the service that Lefkofsky wants to remedy.

Tempus is Eric Lefkofsky’s latest start up and his mission statement is to fundamentally change the way that cancer care and cancer research is approached. Tempus is an analytical piece of software that looks at a patient’s molecular and clinical data before streamlining the process into a digital interface. This data is primarily focused on genomic information. This data is then accessible by cancer care clinics and hospitals all around the country, at least those that interface with the Tempus system. Lefkofsky’s plan was to introduce a new operating system, sort of like a digital blanket, that lay directly over top the already implemented EHRs.

Lefkofsky is focused on the development of genome sequencing because he believes it to be the key to unlock cancer research. Lefkofsky believes, and medical research backs him up, that the human gene has the information required to find more effective paths to treatment for cancer.

To know more visit @: lefkofskyfoundation.com/about-eric-lefkofsky/

[Top]

Securus Technology-Uniting Convicts with their Families

Being separated from family members can be hard a thing with in life. It is, therefore, a sad moment when one of our family members is convicted of a crime. Despite them having done illegal things, we still want them close to us. As the saying goes, blood is thicker than water.

Life has made the life for inmates’ family easier. Jail life now appears like, the inmate went for a long business trip. This is because they can keep in touch with the outside world regularly.

Securus technology is the company behind this improvement. The creative staff has put their minds together and provided communication gadgets. These devices enable the convicts to make audio or video calls according to their preference.

The family of the inmates (users) has appreciated this improvement. The families have said that the communication has, in some cases, improved the relationship between the families. They further explain that sometimes they couldn’t understand why the convict would do such an awful thing, which they knew would end up separating them from their family. However, it is during this visits that the convicts explain themselves. The relatives get to understand their actions and support them while they complete their sentences.

Other family members say that through the chance that the Securus technology has given them, they have been able to reconcile. Some users say that, before the inmates were jailed, they were not able to track them down. This is because it is to the family issues that the inmate ended up in crime life. Through the communication, the inmates and their families get a chance to talk again.

Securus technology, though its communication gadgets, has helped in recreating the bonds of the inmates and their families. Through this love the convicts experience in their desperate moments, they can easily heal and become better people.

[Top]

Running a profitable business by Todd Lubar

Running business ventures requires a lot of dedication. It one thing that keeps entrepreneurs going. Todd Lubar a successful investor in the real estate business in the United States takes us through some important business aspects. He is currently the President of TDL Global Ventures.

For one to run a successful business, experience is a crucial factor. Todd who has had over 20 years working in the credit and finance sector, today applies his skills when selling the mortgage adoption policy to his clients. It is this experience in his previous workstations that make him realize what to do and not what to in this industry. He then attributes the success of every business person to desire in helping others. This is the most important attribute that every business person should possess. The first priority should always be assisting your clients to reach their goals. In the world we live today, the most helpful means of assisting people is by giving them access to financial services. Giving your clients access to loans means they can be able to navigate around the obstacles they face in their daily lives with ease. Todd Lubar as an entrepreneur is a firm believer in this policy. As part of his work, he runs a program that provides his clients with what they seek.

Todd Lubar on Linked In says the only way to stay constantly profitable is first by possessing the will to help people reach their goals. If you can get this right you can always be assured of being profitable in your business ventures. It is how many people you can assist and in what ways you can do it that determines how successful you’re likely to be. Todd Lubar in his work applies the skills and expertise he has acquired from the finance and real estate sectors to find his clients and always remain profitable in whatever he does.

Todd Lubar says that a business does not just become profitable just overnight. It may take years of hard work before you can finally realize satisfactory returns. Getting the business plan right and always staying on track is the most important thing. Once the business is profitable, the thing is just to keep the momentum going forward.

https://www.google.com/search?q=todd+lubar&rlz=1C1CHBF_enUS693US693&espv=2&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwiaxufeoePSAhXLvrwKHRzJCD8QsAQINw

[Top]

“Dr. Clay Siegall – Fervently Fighting Cancer”

Located in Washington State’s Bothell Cascade Business Park, you will discover the headquarters of Seattle’s Genetics, Inc., a biotechnology company with a passion for treating cancer, which was established in 1998.

Within one of these buildings, you will find The Board’s President, Chief Executive Officer and Chairman, Dr. Clay Siegall.

Here you will find constant research in developing and manipulating antibodies, in which an immune response is triggered, weakening or destroying the antigens or toxins in the affected body.

This plan of action can result in Seattle Genetics becoming a major player in the pharmaceutical field.

With an estimated market value of $10 billion, along with 900 workers and the intention of adding 200 more in the future, this company rates as the biggest biotech institution in Washington State.

The primary drug for Seattle Genetics is Adcetris.

It is earmarked for treating Hodgkin’s disease, a condition in which there is an increase in the size of the lymph tissues and if the condition worsens, the liver and spleen might have issues as well.

Our rigorous research, if Adcetris prove to overcome cancer cells, this would be cutting-edge therapy and part of Oncologists first line of defense.

Of course, this would result in exponential profits in yearly sales.

This is only one of the eleven drugs Seattle Genetics have in their cancer-fighting arsenal.

Dr. Siegall is dedicated to transforming the company from biotech to a pharmaceutical enterprise.

He has also taken steps to delve into international marketing of the drugs, by opening a business in Switzerland, so Seattle Genetics can promote and distribute their own products.

Although the state of the economy and political climate might be baffling at times, Siegall remains positive about the progress of the company. He enjoys what he is doing and he does not get distracted, while advancing toward his goals.

Dr. Clay Siegall is the co-founder of Settle Genetics, Inc. With him at the helm, the company has produced a variety of cancer treatment medications, with their primary drug Adcetris getting advanced approval by the Federal Food and Drug Administration (FDA).

He received a Bachelor of Science from the University of Maryland and a Ph.D. in Genetics from Georgetown University.

Previously Siegall worked for other medical facilities including, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute.

While remembering the words of one of his previous mentors, in which he stated, “Don’t take no for an answer”, Dr. Clay Siegall continues to persevere in the fight against cancer.

[Top]

Sheldon Lavin, OSI Group CEO

Sheldon Lavin, Chairman and Chief Executive Officer of OSI Group, LLC, has become a titan in the meat industry over his storied career, which to this day, has lasted over forty years. He has taken OSI Group from small supplier of meat for the fast food giant McDonald’s, into an international supplier of food products to major food service companies around the world. While he is currently at the top of his field, over the span of nearly five decades, his career has transformed considerably. Mr. Lavin’s career in meat industry began in a very different direction. The head of OSI Group was initially a very successful investor and executive in the banking industry, while also heading his own financial consulting firm.

Today, OSI Group employs nearly 20,000 people around the world, and due to the family oriented culture that Mr. Lavin has helped to implement throughout, the company has consistently had a very high retention rate among employees, with many employees staying with the company for a decade or more. Mr. Lavin’s foray into the meat industry began in 1970 when he was asked to secure funding for Otto and Son’s, the precursor to OSI Group. The deal with Otto and Sons would allow them to build a major meat processing facility, and in turn, become the top supplier of hamburgers to McDonald’s Corporation in the midwest. While arranging the deal with Otto and Son’s, Mr. Lavin was asked by the bank to come aboard, taking an ownership position with the company. While Mr. Lavin initially declined to take an ownership position, he was able to negotiate a condition with the heads at Otto and Son’s, that if he were to decide to come aboard at a later date, his financial investment would be on par with the conditions set for Otto family. By the late 70’s, after serving as a consultant at Otto and Son’s, Mr. Lavin was convinced by McDonald’s Corporation to become a full-time partner with the company, soon to be called OSI Group, in order to continue a progressive relationship between both parties.

Read More: www.rmhc.org/board-of-trustees

[Top]